Merck Shares Rise After Partner's Lung Cancer Trial Meets Primary Goal
Merck & Co. shares gained following Kelun-Biotech's announcement that a late-stage study of the experimental antibody-drug conjugate sac-TMT, when given with Merck's immunotherapy Keytruda, met its primary endpoint in first-line advanced lung cancer patients without PD-L1 expression. The combination improved progression-free outcomes versus Keytrud…